Precision drug delivery
The next generation of targeted cancer therapy
Conqueror Biopharma is developing a proprietary precision-oncology platform designed to overcome key limitations of conventional antibody–drug conjugates, including normal-tissue expression of internalizing targets, variable target density, and inconsistent intracellular delivery.
Our platform is designed to harness tumor-selective, underutilized biological markers to enable conditional and efficient intracellular delivery of potent therapeutics.
By expanding the range of tumor-associated features that can support targeted drug delivery, we aim to improve selectivity, widen the therapeutic window, and advance safer, more effective precision-oncology treatments.
Why this matters
✓
Defined Composition
Reproducible, batch-to-batch consistent manufacturing
✓
Inherent Selectivity
Reduced systemic toxicity
✓
Modular Design
Adaptable to multiple targets and payloads